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Mesenchymalstemcells canbeisolatedfromalmostanyadulttissue.Inthispaper wefocusonbonemarrow-derived mesenchymal
stem cells which have captured the interest of researchers since their introduction because of the promising potential of tissue
regeneration and repair. They are known for their ability to self-renew and diﬀerentiate into diverse lineages while maintaining
lowimmunogenicity.The exact mechanismsbehind howthese cells work still remain unclear, andthere is a continuing shiftin the
paradigms that support them. There has been extensive research in multiple organ systems; however, the genitorurinary system
has been vastly underrepresented. This article discusses the background behind bone marrow-derived mesenchymal stem cells
and they are currently being applied to the urinary bladder in the realm of tissue engineering. We also postulate on their future
applications based on the current literature in other organ systems.
1.Introduction
Bone marrow mesenchymal stem cells (MSCs) were ﬁrst
identiﬁed in the 1960s by Ernest A McCulloch and James
E. Till as being a clonal source of cells for further use [1].
Further experiments in the 1970s and 80s by Friedenstein et
al. expanded upon the potential of MSCs by demonstrating
their capacity for self-renewal and multilineage diﬀerentia-
tion[2,3].Intheensuingdecadesextensiveresearchhasgone
into unlocking the therapeutic potential for MSCs.
Stem cells are deﬁned by their potency, the capacity
to diﬀerentiate into a variety of cells, and cell lineages.
Embryonic stem cells, as their name implies, are cul-
tured from the inner cell mass of blastocysts during early
embryonic development and have received a good deal
of attention due to their potential for misuse and ethical
consideration [4]. These cells are undiﬀerentiated at the time
of harvest and therefore are pluripotent with the ability
to develop into any cell type. MSCs are an adult stem
cell isolated not only from bone marrow but also from
most adult tissue including adipose, liver, amniotic ﬂuid,
lung, skeletal muscle, and kidney. However, one advantage
of bone marrow is the ease with which these cells are
cultured. Furthermore, their diﬀerentiation into osteocytes,
adipocytes, chondrocytes, hepatocytes, and myocytes has
been extensively characterized, with the further possibility
of diﬀerentiation into cardiomyocytes and neurons [5–8].
Even more recent investigations suggest that MSCs can
diﬀerentiate into endodermal lineage as well [7, 9].
There are many reasons why researchers have been
enamored by MSCs. Even though only a small percentage
of cells in the bone marrow are MSCs, they are easily
isolated because of their aﬃnity and adherence to plastic
[3, 8]. Even a small number of MSC can multiply into
millions ofcellsunderthe right cultureconditions. Extensive
protocols have been delineated for culturing stem cells in a
variety of animals including humans. MSCs do not express
MHC II rendering them nonimmunogenic, thus precluding
the need for lifelong immunosuppression with allogenic
transplantation [7]. Also, intravenous injection allows for
safe, fast, and easy transplantation of,F MSCs into the host
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There are currently 119 clinical trials that have or
will involve MSCs (http://www.clinicaltrials.gov/). While
there have been great strides in the translation of the
bench research into clinical practice, there is still very little
understood about the exact nature of the MSCs that are
being described. There are currently no universal markers
for identifying MSCs or characterizing their subpopulations
andthusastandardization process has beendiﬃcult[11,12].
Furthermore, there seems to be a discrepancy between the
behavior of in vitro expanded MSCs and fresh, nonmanipu-
lated MSCs and their microenvironmental interactions [13].
1.1. Proposed Mechanisms of MSCs for Repair and Regenera-
tion. B e c a u s eM S C sw e r en o t e dt od i ﬀerentiate into various
cell lines, it was thought initially that the mechanism in
which MSCs acted was through engraftment and diﬀerentia-
tioninto theinjuredtissue. Infact engraftedMSCshavebeen
identiﬁed at sites ofinjury in lung [14], liver [15], heart [10],
kidney [16], and brain [17] with an associated improvement
in function. There have been numerous reports of systemic
infusions of MSCs leading to functional improvements
based on this paradigm of engraftment and diﬀerentiation;
however, ithas been challenged as clinicallyrelevant [14, 18].
It is not only diﬃcult to demonstrate extensive engraftment
of cells, but also many cells are trapped in the lungs
after systemic injection [10, 18]. Furthermore, prolonged
responses of therapeuticeﬀectwere notedafter identiﬁcation
of MSCs had ceased. Thus, it became evident that another
mechanism in which MSCs exerted their reparative beneﬁt
existed.
Extensive research has been performed showing MSCs
ability to remold damaged cardiac tissue after myocardial
infarction [10], improve ﬁbrotic responses in lung disease
[19], and facilitate repair of spinal cord [20], bony and
cartilaginous injury. The variety in the underlying nature
of the aforementioned injuries (ischemia, ﬁbrosis, fracture,
etc.) exempliﬁes that the fundamental basis of MSCs in a
repair model is their ability to identify the site of injury via
various secreted chemotactic factors [21].
Therefore, research into other mechanisms in which
MSCs could exert their eﬀect began, and it is now believed
that it is the paracrine “trophic activity” [22]o fM S C st h a t
provides the regenerative microenvironment. The secretion
of bioactive materials by MSCs in response to injury
mitigates the inﬂammatory response and in turn decreases
injury and promotes repair [22, 23]. This secretion acts not
only by directly initiating intracellular pathways but also
by indirectly inciting another cell in the area to secrete
a functionally active agent [24]. Inhibition of apoptosis,
scar formation and promotion of angiogenesis, as well as
stimulation ofinjured tissue to diﬀerentiateinto regenerative
units, are the downstream results of such bioactive agents.
1.2.ImmunomodulatoryResponse. Morerecently,MSCshave
also been shown to have an in vivo immunomodulatory
eﬀect, most notably in graft versus host disease [11, 25].
Extensive in vitro studies demonstrate that MSCs lead
to inhibition of TNF-α and INF-α production with an
increase in IL-10, thereby limiting Tcell expansion [22].
Via prostaglandin E2, MSCs can inhibit natural killer cell
proliferation and cytotoxicity in vitro, as well as steer mono-
cytes and mature dendritic cells to an immature dendritic
cell state, rendering them more susceptible degradation by
natural killer cells [25].
Another group looked at the response of MSCs to the
proinﬂammatory cytokine IFN-γ or in combination with
TNF, IL-1α,a n dI L - 1 β and found that MSCs secreted
chemoattractants for T cells as well as inducible nitric
oxide synthetase. The subsequent production of nitric oxide
inhibited the T cell activation [26]. However, this same
mechanism of T cell suppression was not found across all
species, and while human and monkey MSCs did not induce
nitric oxide synthetase, T cells were still suppressed in a
diﬀerent manner [26].
It is likely a combination of the paracrine activity of the
MSCs and direct cell contact that allows MSCs to have both
a reparative and immunomodulatory eﬀect. Their response
to injury in the absence of invading organisms produces
a negative feedback loop to hinder the otherwise excessive
inﬂammatory and immune response produced in many
disease states [18]. It is from this knowledge that many of the
clinical experiments both in vitro and in vivo have evolved
and contributed to the breadth and variety in which MSCs
are being applied.
2.Mesenchymal StemCellsinthe Bladder
Asresearch intoutilizingMSCshasmovedforward, extensive
information has been obtained into the venues in which
MSCs can be applied. The application of MSCs has been
well established in several organ systems, most notably
musculoskeletal, vascular, and reticuloendothelial, however
it seems that less has been done in the genitourinary system.
In this paper, we will focus on the research and applications
of MSCs speciﬁcally in the bladder.
Tissue engineeringwas ﬁrstinitiated inboneremodeling,
withtheconceptofapplyingMSCstoascaﬀoldandimplant-
ing into bony repair sites [22]. In the bladder, initial interest
has focused on tissue regeneration in hopes of allowing
an autologous bladder augmentation and circumventing
the multiple morbidities associated with enterocystoplasty.
However, as more information regarding diﬀerentiation
potential, successful gene therapy, and immunomodulation
has progressed, the number of potential applications of
MSCs to bladder research has increased as well.
2.1. Tissue Regeneration. The ideal application of bladder
tissue regenerationis to developa functional urinary bladder
for patients with either congenital or acquired bladder
defects. Currently, this means augmenting a poorly com-
pliant, ﬁbrotic bladder, reconstructing a partially removed
bladder or actually creating a reservoir from intestine.
Without surprise, MSCs have found their way into this arena
and currently are showing extreme promise as a source of
cells for graft development.Stem Cells International 3
An important advance in tissue regeneration was deter-
mining that MSCs could be induced into tissue speciﬁc
diﬀerentiation. MSCs cultured in conditioned mediums
acquire a smooth muscle cell phenotype, staining positively
for alpha-smooth muscle actin, myosin, and calponin [27,
28]. Culturing in the presence of other myogenic growth
factors can also lead to a phenotypic proﬁle of smooth
muscle [27, 29]. Urothelium can also induce mesenchyme
into smooth muscle diﬀerentiation, [30] a property that will
be extremely useful for future in vivo MSC studies.
Previously it was thought that MSCs only diﬀerentiated
intostromal tissues.However,recentreportsare encouraging
thatinappropriateenvironments, MSCsarecapableofendo-
dermaldiﬀerentiationaswell [9,31,32].XenograftsofMSCs
and embryonicbladdermesenchyme were incubatedundera
renal capsule and after 6 weeks showed a bladder structure,
includingbothMSC-derivedurotheliumandsmoothmuscle
with a lumenoid cavity [31]. Tian et al. were also able to
induce urothelial diﬀerentiation from MSCs when grown in
urothelial cell-conditioned medium [9]. Another group was
surprised to ﬁnd marked urothelial cells on an MSC seeded
SIS (small intestinal submucosa) graft in a porcine bladder
augmentation suggesting that MSCs transdiﬀerentiated into
the urothelial cells [33].
Tissue regenerative studies involving the bladder have
primarily focused on using anu n d e r l y i n gm a t r i xt h a ti s
either seeded with cells or left unseeded for in vivo inﬁl-
tration [9, 27, 34, 35]. Initial attempts have been hindered
by poor scaﬀold materials and cells that do not contribute
to creating the smooth muscle component necessary for
contractility and compliance that characterizes the bladder.
MSCs, for many reasons previously discussed, are emerging
as an extremely promising cell population for tissue regener-
ation. Kanematsu et al. transplanted GFP-labeled MSCs into
lethally irradiated rats and determined the recruitment of
MSCs to an acellular matrix graft on the dome of the rat
bladder eight weeks later. Within two weeks the MSCs were
seen to be populating the graft and twelve weeks later had
not only reconstituted the smooth muscle cell layer but also
induced native smooth muscles cells to inﬁltrate the graft as
well [27]. Recent investigations have lookedat biodegradable
scaﬀolds including small intestinal submucosa [36] (SIS),
elastomeric poly(1,8 octanediol-co-citrate) based thin ﬁlms
[35], and 3D nanoﬁbrous scaﬀolds [34] seeded with bone
marrow-derived stromal cells with favorable results.
After identifying SIS as a suitable matrix for cell seeding
and bladder augmentation [37], Zhang et al. compared
MSC-seeded SIS to bladder smooth muscle cell-seeded SIS
both in vitro and in vivo and showed that MSCs had similar
cell proliferation, contractile phenotype and histological
appearance to smooth muscle cells [36]. The grafts showed
excellent penetration of the MSCs with positive staining for
alpha-smooth actin. However, only two of the augments did
not show shrinkage (one MSC seeded, one smooth muscle
cell seeded) limiting the in vivo functional interpretation of
this study. Bladder reconstitution was improved and noted
earlier in SIS bladder augments in a rat model [38].
Tian et al. were able to diﬀerentiate MSCs into smooth
muscle cells on a nanoﬁbrous 3D poly-L-lactic acid scaﬀold.
The porous structure allows a favorable microenvironment
for SMC diﬀerentiation and regeneration and even showed
capillary formation after one month of subcutaneous incu-
bation [9, 34]. Since MSCs have identiﬁed their potential
as a cell source for seeding scaﬀolds, the search continues
for the scaﬀold that is the most functionally equivalent
to the bladder. Sharma et al. recently evaluated a novel
synthetic elastomeric scaﬀold that was seeded with MSCs
and augmented onto rat bladders [35] .A f t e r1 0w e e k st h e
harvested graft showed a robust, trilayered architecture with
retained pliability compared to the unseeded graft [35]. The
urothelial layer consisted of local ingrowth from the native
rat bladder; however, well-formed smooth muscle bundles
were regenerated from MSCs. Furthermore, it is felt that
MSC-pseeded scaﬀolds that allow for repeated contraction
and expansion contribute to the maturation of the MSCs
by stimulating smooth muscle diﬀerentiation [34, 35]. All
of these results are promising, and there is still exceptional
enthusiasm in the realm of bladder tissue engineering with
MSCs as donor cells at the forefront.
2.2. Repair and Fibrosis. As exciting as it seems to use MSCs
for de novo tissue regeneration, more promising is the
application of MSCs in tissue remodeling and repair. Several
modelsofﬁbrosisinlung,heart,andliverhaveutilizedMSCs
inmodulating theﬁbroticresponse. Ratstreatedwith carbon
tetrachloride (CCL4) or dimethylnitrosamine (DMN) to
induce an experimental liver ﬁbrosis similar to humans were
systemically administered MSCs. Compared to controls, rats
treated with MSCs showed not only and improvement in
survival but also an improvement in collagen deposition,
ﬁbrotic index, an improved liver function [15]. Ortiz et al.
evaluated the ﬁbrotic response of lung tissue to bleomycin
with and without treatment of MSCs [19]. Again noted was
an improvement in inﬂammation and ﬁbrosis in response
to bleomycin in MSC-treated mice. Mice treated with MSCs
were also noted to decrease expression of matrix metallopro-
teinases 2 and 9. In both models, earlier administration of
MSCs after the insult leads to the greatest improvement in
ﬁbrosis.
Very little research has been performed investigating
the recruitment of MSCs to an injured bladder model.
Bladder ﬁbrosis is an untoward eﬀect of bladder outlet
obstruction which can aﬀect both children and adults.
In a partially obstructed bladder outlet model, Tanaka et
al. showed recruitment of bone marrow-derived cells in
both the urothelium and stromal layers [39]. GFP-labeled
fetal liver cells were used to repopulate irradiated bone
marrow in mice, and GFP-positive bone marrow-derived
cells were isolated in ﬁbrotic bladders after 12 weeks of
partial obstruction. There was an increase in expression of
chemokine CCL2 in the obstructed bladders which has been
associated with ﬁbrosis in other organs. This research sets up
a platform for further investigation into the role of MSCs in
ﬁbrotic conditions of the bladder and for determining key
factors in the recruitment of MSCs to the injured bladder.
A surprise outcome of improved remodeling after cryo-
induced injury to the bladder was noted in a study that was4 Stem Cells International
looking for amniotic ﬂuid MSCs and bone marrow MSCs
diﬀerentiation into smooth muscle cells [40]. The group
directly transplanted the MSCs into the site of injury in the
rat bladder, but only found a very small amount of MSCs
diﬀerentiated into the smooth muscle cells that contributed
to the repair process. Instead they found a reduction in the
hypertrophythat generallyresults fromthe regenerationafter
such an injury [40]. Their results further support the shift in
role of MSCs in repair from engraftment and diﬀerentiation
to a support and mediator.
2.3. Gene Therapy. Another application of MSCs has been
in the realm of genetic therapy. MSCs have emerged as
potential vehicles for the delivery of transgenes because of
their characteristic tissue speciﬁc homing, long life span,
and low potential for immunologic response [13]. Among
other methods, viral vectors are used in the introduction
of the transgenes. Lentivirus-transduced murine MSCs were
able to maintain their in vitro multipotency and the, MSCs
were subsequently identiﬁed in vivo in minimally injured
transplanted mice [41]. Gene-modiﬁed MSCs are being
utilized in vivo in a variety of inherited neurologic and blood
disordersaswell asincardiovasculardisease,musculoskeletal
disease, and tumor growth [13, 42, 43].
A study using MSCs in an acute lung injury model also
showed that MSCs injected after endotoxin injury showed
a reduction in edema, vascular injury, and pulmonary
hypertension [44]. Another group proceeded to infect MSCs
with angiopoietin-1 (Ang-1), an important mediator in the
pathologic changes that occur in the lung in response to
injury [45]. Mice that were treated with MSC-Ang-1 showed
signiﬁcant improvement even over mice treated with MSCs
alone in regards to lipopolysaccharide-induced lung injury.
Increasedexpression ofAng-1was notedinmicetreatedwith
the transfected MSCs and persisted for 14 days until sacriﬁce
[45].
Transcribing these models to bladder ﬁbrosis, antitumor
therapy or interstitial cystitis is certainly not diﬃcult to
envision. Increased expression of a substance further capable
of modulating the extracellular matrix may improve the
already postulated attenuation of ﬁbrosis created by MSCs.
Potential for targeted chemotherapy to prevent recurrences
of superﬁcial bladder cancer could replace intravesical
therapy. Gene therapy for improving the glycosaminoglycan
(GAG)layerinurotheliuminpatientswithinterstitialcystitis
could provide further information to the etiology of a
confounding clinical problem.
3.Conclusion
MSCscontinue toallure researchers with upto5–10papers a
day regarding MSCs being published. Further elucidation of
the biochemical pathways that lead to their speciﬁc homing
to various injured sites will be crucial in the trajectory
of future research eﬀorts. Standardization in the culturing
techniques and identiﬁcation of injected MSCs will be
necessary for replication of work. In the speciﬁc realm of
the genitourinary system, MSCs hold much promise for the
future of tissue engineering, treatment of ﬁbrotic bladders,
and gene therapy.
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